Laura M. Mafla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura M. Mafla has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kevin M. Motz
Department of Otolaryngology – Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
4 shared publications - Raymond J. So
Department of Otolaryngology‐Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
4 shared publications - Alexander T. Hillel
Department of Otolaryngology‐Head and Neck Surgery Johns Hopkins School of Medicine Baltimore Maryland USA
3 shared publications Ibrahim Abd‐Elazem
Department of Otolaryngology Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
3 shared publicationsSamuel L. Collins
Department of Otolaryngology Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
3 shared publications- Yee Chan‐Li
Department of Otolaryngology Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
3 shared publications
Latest Publications
- 8 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 251-261
S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis
Objective: Iatrogenic Laryngotracheal Stenosis (iLTS) is a pathologic narrowing of the laryngotracheal airway secondary to intubation injury. Inflammation plays a critical role in iLTS pathogenesis. However, the local immune mediators promoting inflammation and subsequent fibrosis remain poorly understood. Transcriptomic analysis of iLTS specimens using single‐cell RNA sequencing has revealed increased expression of the damage‐associated molecular pattern (DAMP), S100A8/A9. The goal of this study is to define the role of S100A8/A9 in iLTS pathogenesis in vivo. Methods: S100A8/A9 expression was assessed using single‐cell RNA sequencing and immunofluorescence in human iLTS and unaffected tracheal controls. To assess the fibrogenicity of S100A8/A9, iLTS‐induced mice were treated with recombinant S100A8/A9 (0.1 mg/kg) or a vehicle control. Fibrosis was assessed by measurement of tracheal lamina propria (LP) thickness and fibrosis‐related gene expression. Results: Immunofluorescence of human iLTS specimens demonstrated increased expression of S100A8/A9 in the LP compared to controls. In iLTS‐induced mice, S100A8/A9 treatment resulted in greater LP thickness compared to control‐treated mice (117.7 ± 23.72 vs. 67.7 ± 33.11 μM, p = 0.03). Gene expression analysis demonstrated a 4.42 ± 0.73 fold increase in Col1a1 expression in S100A8/A9‐treated iLTS mice ( p = 0.01). S100A8/A9's downstream regulatory protein MYD88 is increased in human iLTS and in iLTS mice treated with S100A8/A9. Conclusion: S100A8/A9 is abundant in human iLTS and promotes fibrosis in a murine model. Targeting S100A8/A9 and its downstream signaling protein MYD88 may be an effective treatment strategy to attenuate iLTS. Investigation into therapies that target S100A8/A9 signaling is warranted. Level of Evidence: NA.
- 8 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 251-261
S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis
Objective: Iatrogenic Laryngotracheal Stenosis (iLTS) is a pathologic narrowing of the laryngotracheal airway secondary to intubation injury. Inflammation plays a critical role in iLTS pathogenesis. However, the local immune mediators promoting inflammation and subsequent fibrosis remain poorly understood. Transcriptomic analysis of iLTS specimens using single‐cell RNA sequencing has revealed increased expression of the damage‐associated molecular pattern (DAMP), S100A8/A9. The goal of this study is to define the role of S100A8/A9 in iLTS pathogenesis in vivo. Methods: S100A8/A9 expression was assessed using single‐cell RNA sequencing and immunofluorescence in human iLTS and unaffected tracheal controls. To assess the fibrogenicity of S100A8/A9, iLTS‐induced mice were treated with recombinant S100A8/A9 (0.1 mg/kg) or a vehicle control. Fibrosis was assessed by measurement of tracheal lamina propria (LP) thickness and fibrosis‐related gene expression. Results: Immunofluorescence of human iLTS specimens demonstrated increased expression of S100A8/A9 in the LP compared to controls. In iLTS‐induced mice, S100A8/A9 treatment resulted in greater LP thickness compared to control‐treated mice (117.7 ± 23.72 vs. 67.7 ± 33.11 μM, p = 0.03). Gene expression analysis demonstrated a 4.42 ± 0.73 fold increase in Col1a1 expression in S100A8/A9‐treated iLTS mice ( p = 0.01). S100A8/A9's downstream regulatory protein MYD88 is increased in human iLTS and in iLTS mice treated with S100A8/A9. Conclusion: S100A8/A9 is abundant in human iLTS and promotes fibrosis in a murine model. Targeting S100A8/A9 and its downstream signaling protein MYD88 may be an effective treatment strategy to attenuate iLTS. Investigation into therapies that target S100A8/A9 signaling is warranted. Level of Evidence: NA.
- 27 November 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (5) , 1724-1731
Serum S100A8 / A9 Correlates to Surgery‐Free Interval in Idiopathic Subglottic Stenosis
Objective: Idiopathic subglottic stenosis (iSGS) is a progressive fibrotic condition of the subglottis that presents in women of northern European descent. Endoscopic dilation is a common surgical approach to management of iSGS. The surgery‐free interval, or the time between endoscopic dilation procedures is considered an indicator of disease severity. Variations in surgery‐free intervals among iSGS patients underscore the necessity for prognostic biomarkers. The objective of this study was to explore serum levels of the damage‐associated molecular pattern S100A8/A9 as a prognostic biomarker in iSGS. Methods: Serum from 20 iSGS patients and eight healthy controls was collected and S100A8/A9 levels were quantified using an ELISA. Patient data, including demographics and surgery‐free intervals, were obtained from medical records. Serum S100A8/A9 levels were compared to surgery‐free intervals. S100A8/A9 was also assessed using gene expression and immunofluorescence in iSGS specimens. Results: S100A8/A9 was significantly elevated ( p = 0.0413) in the serum of iSGS patients compared to controls (312.75 vs. 181.49 ng/mL). Linear regression analysis revealed a correlation ( p = 0.009) between S100A8/A9 levels and endoscopic surgery‐free interval. S100A8/A9 was significantly elevated ( p = 0.0011) in patients with surgery‐free intervals less than 1 year (455.2 ± 60.45 ng/mL; n = 8) compared to patients with intervals over 1 year (292.5.93 ± 162.4; n = 6). Conclusion: S100A8/A9 is increased in the serum and tissue of patients with iSGS. In this cohort of iSGS patients, serum S100A8/A9 was associated with surgery‐free intervals, potentially representing a prognostic biomarker. Further research within a larger cohort is needed to confirm these findings. Level of Evidence: 3 Laryngoscope , 135:1724–1731, 2025
- 27 November 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (5) , 1724-1731
Serum S100A8 / A9 Correlates to Surgery‐Free Interval in Idiopathic Subglottic Stenosis
Objective: Idiopathic subglottic stenosis (iSGS) is a progressive fibrotic condition of the subglottis that presents in women of northern European descent. Endoscopic dilation is a common surgical approach to management of iSGS. The surgery‐free interval, or the time between endoscopic dilation procedures is considered an indicator of disease severity. Variations in surgery‐free intervals among iSGS patients underscore the necessity for prognostic biomarkers. The objective of this study was to explore serum levels of the damage‐associated molecular pattern S100A8/A9 as a prognostic biomarker in iSGS. Methods: Serum from 20 iSGS patients and eight healthy controls was collected and S100A8/A9 levels were quantified using an ELISA. Patient data, including demographics and surgery‐free intervals, were obtained from medical records. Serum S100A8/A9 levels were compared to surgery‐free intervals. S100A8/A9 was also assessed using gene expression and immunofluorescence in iSGS specimens. Results: S100A8/A9 was significantly elevated ( p = 0.0413) in the serum of iSGS patients compared to controls (312.75 vs. 181.49 ng/mL). Linear regression analysis revealed a correlation ( p = 0.009) between S100A8/A9 levels and endoscopic surgery‐free interval. S100A8/A9 was significantly elevated ( p = 0.0011) in patients with surgery‐free intervals less than 1 year (455.2 ± 60.45 ng/mL; n = 8) compared to patients with intervals over 1 year (292.5.93 ± 162.4; n = 6). Conclusion: S100A8/A9 is increased in the serum and tissue of patients with iSGS. In this cohort of iSGS patients, serum S100A8/A9 was associated with surgery‐free intervals, potentially representing a prognostic biomarker. Further research within a larger cohort is needed to confirm these findings. Level of Evidence: 3 Laryngoscope , 135:1724–1731, 2025
- 13 May 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (10) , 4239-4245
An Ovine Model Yields Histology and Gene Expression Changes Consistent with Laryngotracheal Stenosis
Objectives: Animal models for laryngotracheal stenosis (LTS) are critical to understand underlying mechanisms and study new therapies. Current animal models for LTS are limited by small airway sizes compared to human. The objective of this study was to develop and validate a novel, large animal ovine model for LTS.Methods: Sheep underwent either bleomycin‐coated polypropylene brush injury to the subglottis (n = 6) or airway stent placement (n = 2) via suspension microlaryngoscopy. Laryngotracheal complexes were harvested 4 weeks following injury or stent placement. For the airway injury group, biopsies (n = 3 at each site) were collected of tracheal scar and distal normal regions, and analyzed for fibrotic gene expression. Lamina propria (LP) thickness was compared between injured and normal areas of trachea.Results: No mortality occurred in sheep undergoing airway injury or stent placement. There was no migration of tracheal stents. After protocol optimization, LP thickness was significantly increased in injured trachea (Sheep #3: 529.0 vs. 850.8 um; Sheep #4: 933.0 vs. 1693.2 um; Sheep #5: 743.7 vs. 1378.4 um; Sheep #6: 305.7 vs. 2257.6 um). A significant 62‐fold, 20‐fold, 16‐fold, 16‐fold, and 9‐fold change of COL1, COL3, COL5, FN1, and TGFB1 was observed in injured scar specimen relative to unaffected airway, respectively.Conclusion: An ovine LTS model produces histologic and transcriptional changes consistent with fibrosis seen in human LTS. Airway stent placement in this model is safe and feasible. This large airway model is a reliable and reproducible method to assess the efficacy of novel LTS therapies prior to clinical translation.Level of Evidence: N/A Laryngoscope, 134:4239–4245, 2024
- 13 May 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (10) , 4239-4245
An Ovine Model Yields Histology and Gene Expression Changes Consistent with Laryngotracheal Stenosis
Objectives: Animal models for laryngotracheal stenosis (LTS) are critical to understand underlying mechanisms and study new therapies. Current animal models for LTS are limited by small airway sizes compared to human. The objective of this study was to develop and validate a novel, large animal ovine model for LTS.Methods: Sheep underwent either bleomycin‐coated polypropylene brush injury to the subglottis (n = 6) or airway stent placement (n = 2) via suspension microlaryngoscopy. Laryngotracheal complexes were harvested 4 weeks following injury or stent placement. For the airway injury group, biopsies (n = 3 at each site) were collected of tracheal scar and distal normal regions, and analyzed for fibrotic gene expression. Lamina propria (LP) thickness was compared between injured and normal areas of trachea.Results: No mortality occurred in sheep undergoing airway injury or stent placement. There was no migration of tracheal stents. After protocol optimization, LP thickness was significantly increased in injured trachea (Sheep #3: 529.0 vs. 850.8 um; Sheep #4: 933.0 vs. 1693.2 um; Sheep #5: 743.7 vs. 1378.4 um; Sheep #6: 305.7 vs. 2257.6 um). A significant 62‐fold, 20‐fold, 16‐fold, 16‐fold, and 9‐fold change of COL1, COL3, COL5, FN1, and TGFB1 was observed in injured scar specimen relative to unaffected airway, respectively.Conclusion: An ovine LTS model produces histologic and transcriptional changes consistent with fibrosis seen in human LTS. Airway stent placement in this model is safe and feasible. This large airway model is a reliable and reproducible method to assess the efficacy of novel LTS therapies prior to clinical translation.Level of Evidence: N/A Laryngoscope, 134:4239–4245, 2024
- 25 August 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (1) , 179-186
Murine Model of Airway Fibrosis has Anatomic, Physiologic, and Molecular Congruency to Human iSGS
Objective: To narrow knowledge gaps in the pathophysiology of idiopathic subglottic stenosis (iSGS) through comparison of a murine subglottic stenosis model with iSGS.Study Design: In vivo animal study.Setting: Academic institution.Methods: Murine samples/measurements were obtained from mice that underwent chemomechanical injury with a wire brush and bleomycin. Human samples/measurements were obtained from iSGS patients. Anatomic, physiologic, and epithelial molecular data were collected using histology, human peak expiratory flow (PEF) and murine airway conductance, gene expression analysis with quantitative polymerase chain reaction, and protein analysis with quantitative immunohistochemistry.Results: Anatomic patterns of scars at the subglottis and proximal trachea seen in the murine model are similar to iSGS patients. Subglottic stenosis (SGS) mice had a decrease (P = .0194) in airway conductance compared to healthy controls, similar to a decrease (P = .0001) in predilation PEF versus postdilation in iSGS patients. There was decreased epithelial gene expression of E‐cadherin (ECAD) (P < 0.01), occludin (OCLN) (P < .01), and cytokeratin‐5 (CK5) (P < .05) and protein expression of ECAD (H/M: P < .001), OCLN (H: P < 0.05, M: P < .001), and CK5 (H: P < .001, M: P < .01) in murine SGS and iSGS versus controls.Conclusion: The murine SGS model shows anatomic, physiologic, and molecular congruency with human iSGS, making it a reasonable model to investigate iSGS. The molecular similarities in epithelial barrier dysfunction suggest it may best be suited to explore epithelial mechanisms of iSGS and therapies directed at epithelial reconstitution. This model provides a foundation to collect data that will improve understanding of iSGS, and, ultimately, translate into more accurate animal models for future use.
- 25 August 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (1) , 179-186
Murine Model of Airway Fibrosis has Anatomic, Physiologic, and Molecular Congruency to Human iSGS
Objective: To narrow knowledge gaps in the pathophysiology of idiopathic subglottic stenosis (iSGS) through comparison of a murine subglottic stenosis model with iSGS.Study Design: In vivo animal study.Setting: Academic institution.Methods: Murine samples/measurements were obtained from mice that underwent chemomechanical injury with a wire brush and bleomycin. Human samples/measurements were obtained from iSGS patients. Anatomic, physiologic, and epithelial molecular data were collected using histology, human peak expiratory flow (PEF) and murine airway conductance, gene expression analysis with quantitative polymerase chain reaction, and protein analysis with quantitative immunohistochemistry.Results: Anatomic patterns of scars at the subglottis and proximal trachea seen in the murine model are similar to iSGS patients. Subglottic stenosis (SGS) mice had a decrease (P = .0194) in airway conductance compared to healthy controls, similar to a decrease (P = .0001) in predilation PEF versus postdilation in iSGS patients. There was decreased epithelial gene expression of E‐cadherin (ECAD) (P < 0.01), occludin (OCLN) (P < .01), and cytokeratin‐5 (CK5) (P < .05) and protein expression of ECAD (H/M: P < .001), OCLN (H: P < 0.05, M: P < .001), and CK5 (H: P < .001, M: P < .01) in murine SGS and iSGS versus controls.Conclusion: The murine SGS model shows anatomic, physiologic, and molecular congruency with human iSGS, making it a reasonable model to investigate iSGS. The molecular similarities in epithelial barrier dysfunction suggest it may best be suited to explore epithelial mechanisms of iSGS and therapies directed at epithelial reconstitution. This model provides a foundation to collect data that will improve understanding of iSGS, and, ultimately, translate into more accurate animal models for future use.